• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Thyrotoxic bone disease in women: a potentially reversible disorder.

作者信息

Diamond T, Vine J, Smart R, Butler P

机构信息

Department of Endocrinology, St George Hospital, Kogarah, New South Wales, Australia.

出版信息

Ann Intern Med. 1994 Jan 1;120(1):8-11. doi: 10.7326/0003-4819-120-1-199401010-00002.

DOI:10.7326/0003-4819-120-1-199401010-00002
PMID:8250460
Abstract

OBJECTIVE

To measure changes in spinal and femoral neck bone mineral densities in patients treated for Graves thyrotoxicosis.

DESIGN

Cohort study.

SETTING

Tertiary care center.

PATIENTS

Fifteen women with active Graves thyrotoxicosis. Six patients were premenopausal and nine were postmenopausal. All patients had evidence of thyrotoxicosis as indicated by a raised total serum thyroxine, suppressed serum thyroid-stimulating hormone, and an elevated technetium-99m pertechnetate thyroid scan. A control group of 15 healthy volunteers matched for age, sex, and menopausal status were followed during the same period.

MEASUREMENTS

Bone mineral density was measured by dual-energy x-ray absorptiometry at baseline and after 12 months of antithyroid therapy when euthyroidism had been achieved.

RESULTS

After 12 months of therapy, total serum thyroxine, total serum triiodothyronine, serum alkaline phosphatase, and serum bone Gla-protein activities had returned to normal in all patients (P < 0.001 for all comparison between initial and final biochemical measurements). During this interval, the mean lumbar spine bone mineral increased from an initial value of 1.01 g/cm2 to 1.07 g/cm2, an increase of 6.6% per year (95% CI, 3.6% to 9.6%) (P < 0.001 compared with controls). Increases in femoral neck (1.2%/y; CI, -2.1% to 4.5%; P = 0.2 compared with controls) and femoral trochanter bone mineral (3.2%/y; CI, 2.4% to 8.7%; P = 0.2 compared with controls) were not statistically significant. Using forced-entry multiple regression analysis, the severity of the thyrotoxicosis was independently associated with the percentage increment in lumbar spine bone mineral density after 12 months of antithyroid therapy.

CONCLUSION

Effective treatment of Graves thyrotoxicosis was associated with increases in lumbar spine and femoral neck bone mineral. Although the changes in bone mineral were modest, our data suggest that thyrotoxic bone loss may be a reversible disorder.

摘要

相似文献

1
Thyrotoxic bone disease in women: a potentially reversible disorder.
Ann Intern Med. 1994 Jan 1;120(1):8-11. doi: 10.7326/0003-4819-120-1-199401010-00002.
2
Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of aetiology and menopause.甲状腺功能亢进患者及接受药物治疗的既往甲状腺功能亢进患者的骨质流失:病因及绝经的影响
Clin Endocrinol (Oxf). 1997 Sep;47(3):279-85. doi: 10.1046/j.1365-2265.1997.2261041.x.
3
Hyperthyroidism influences ultrasound bone measurement on the Os calcis.
Osteoporos Int. 1998;8(5):455-9. doi: 10.1007/s001980050091.
4
Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis.接受甲状腺素治疗的女性的骨矿物质密度,无论其既往有无甲状腺毒症病史。
Clin Endocrinol (Oxf). 1994 Oct;41(4):425-32. doi: 10.1111/j.1365-2265.1994.tb02572.x.
5
TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy.促甲状腺激素受体抗体可能预防患有格雷夫斯病和格雷夫斯眼眶病的绝经前和绝经后女性的骨质流失。
Arch Endocrinol Metab. 2018 Mar-Apr;62(2):221-226. doi: 10.20945/2359-3997000000027.
6
Skeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapy.接受长期左旋甲状腺素治疗的绝经前和绝经后女性的骨骼完整性。
Am J Med. 1991 Jul;91(1):5-14. doi: 10.1016/0002-9343(91)90066-7.
7
Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis?内源性亚临床甲状腺功能亢进患者的骨矿物质密度:这种甲状腺状态是骨质疏松症的危险因素吗?
Clin Endocrinol (Oxf). 1993 Nov;39(5):521-7. doi: 10.1111/j.1365-2265.1993.tb02403.x.
8
Change in bone mineral density in patients with hyperthyroidism after attainment of euthyroidism by dual energy X-ray absorptiometry.双能X线吸收法测定甲状腺功能亢进患者甲状腺功能正常后骨矿物质密度的变化
Thyroid. 1994 Summer;4(2):179-82. doi: 10.1089/thy.1994.4.179.
9
Does Graves' disease during puberty influence adult bone mineral density?青春期患格雷夫斯病会影响成人骨密度吗?
Horm Res. 2002;58(4):176-9. doi: 10.1159/000065491.
10
Bone mineral density after surgical treatment for Graves' disease.格雷夫斯病手术治疗后的骨矿物质密度
Thyroid. 1997 Aug;7(4):547-54. doi: 10.1089/thy.1997.7.547.

引用本文的文献

1
High prevalence of laboratory abnormalities indicative of secondary osteoporosis detected by systematic testing.通过系统检测发现,提示继发性骨质疏松的实验室异常情况普遍存在。
JBMR Plus. 2025 May 17;9(7):ziaf089. doi: 10.1093/jbmrpl/ziaf089. eCollection 2025 Jul.
2
Bone microarchitecture and bone mineral density in Graves' disease.格雷夫斯病中的骨微结构和骨矿物质密度
Osteoporos Sarcopenia. 2023 Jun;9(2):70-75. doi: 10.1016/j.afos.2023.05.001. Epub 2023 Jun 1.
3
Vitamin D and bone metabolism in Graves' disease: a prospective study.
格雷夫斯病中维生素 D 与骨代谢:一项前瞻性研究。
J Endocrinol Invest. 2023 Feb;46(2):425-433. doi: 10.1007/s40618-022-01927-y. Epub 2022 Sep 27.
4
Therapy of moderate-to-severe Graves' orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density.静脉注射甲基强的松龙脉冲治疗中重度格雷夫斯眼病与骨密度丢失无关。
Endocrine. 2019 May;64(2):308-315. doi: 10.1007/s12020-018-1823-x. Epub 2018 Dec 1.
5
Leptin is overexpressed in the tumor microenvironment of obese patients with estrogen receptor positive breast cancer.瘦素在雌激素受体阳性乳腺癌肥胖患者的肿瘤微环境中过度表达。
Exp Ther Med. 2017 May;13(5):2235-2246. doi: 10.3892/etm.2017.4291. Epub 2017 Mar 30.
6
Negative correlation between bone mineral density and TSH receptor antibodies in long-term euthyroid postmenopausal women with treated Graves' disease.经治疗的Graves病长期甲状腺功能正常的绝经后女性骨密度与促甲状腺素受体抗体之间的负相关关系
Thyroid Res. 2013 Sep 11;6(1):11. doi: 10.1186/1756-6614-6-11.
7
Metabolic and clinical consequences of hyperthyroidism on bone density.甲状腺功能亢进对骨密度的代谢和临床影响。
Int J Endocrinol. 2013;2013:638727. doi: 10.1155/2013/638727. Epub 2013 Jul 22.
8
Bone disease in thyrotoxicosis.甲状腺毒症中的骨骼疾病。
Indian J Med Res. 2012 Mar;135(3):277-86.
9
Impact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men.男性甲状腺功能亢进症的严重程度、持续时间和病因对骨转换标志物和骨密度的影响。
BMC Endocr Disord. 2011 Aug 6;11:15. doi: 10.1186/1472-6823-11-15.
10
Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease?绝经前 Graves 病女性应用抗甲状腺药物治疗能否逆转骨丢失?
Nutr Metab (Lond). 2010 Sep 1;7:72. doi: 10.1186/1743-7075-7-72.